Celltrion to buy Eli Lilly’s production facility to avoid US tariffs
PositiveFinancial Markets
Celltrion's decision to acquire Eli Lilly's production facility is a strategic move to sidestep potential US tariffs, which could significantly impact their operations. This acquisition not only strengthens Celltrion's manufacturing capabilities but also enhances its position in the competitive pharmaceutical market. By securing local production, they can ensure better supply chain efficiency and cost management, ultimately benefiting consumers and stakeholders alike.
— Curated by the World Pulse Now AI Editorial System